Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeq.
Using a probabilistic model of the clinical and economic burden of rotavirus gastroenteritis (RVGE), we estimated the expected impact of vaccinating a US birth cohort with Rotarix in lieu of RotaTeq. Assuming full vaccination of all children, use of Rotarix - rather than RotaTeq - was estimated to reduce the total number of RVGE events by 5% and associated costs by 8%. On an overall basis, Rotarix would reduce costs by $77.2 million (95% CI $71.5-$86.5). Similar reductions with Rotarix were estimated to occur under an assumption of incomplete immunization of children.
Weycker
Derek
D
Policy Analysis Inc. (PAI), Four Davis Court, Brookline, MA 02445, United States. dweycker@pai2.com
Sofrygin
Oleg
O
Kemner
Jason E
JE
Pelton
Stephen I
SI
Oster
Gerry
G
D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D005260:Female; D005759:Gastroenteritis / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D007114:Immunization / Q000191:economics*; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D015233:Models, Statistical; D012400:Rotavirus Infections / Q000191:economics / Q000453:epidemiology* / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000191:economics* / Q000276:immunology*; D014481:United States / Q000453:epidemiology; D014613:Vaccines, Attenuated / Q000191:economics / Q000276:immunology
C492457:RIX4414 vaccine; C492535:RotaTeq; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated